MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.86% | 30.89% | 31.70% | 57.30% | 44.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.86% | 30.89% | 31.70% | 57.30% | 44.40% |
| Cost of Revenue | 22.78% | 3.01% | -22.02% | -2.12% | -10.27% |
| Gross Profit | 29.30% | 139.31% | 3,428.14% | 1,420.36% | 575.75% |
| SG&A Expenses | 0.71% | -12.16% | -5.18% | 9.17% | -16.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -128.34% | -45.45% | -137.78% | -82.07% | 29.56% |
| Total Operating Expenses | 11.37% | -4.57% | -15.71% | 1.66% | -14.80% |
| Operating Income | 28.85% | 64.24% | 75.12% | 54.12% | 61.67% |
| Income Before Tax | 20.92% | 24.96% | 31.41% | 47.28% | 57.20% |
| Income Tax Expenses | -- | -2,940.91% | -4,511.36% | -4,511.36% | -4,511.36% |
| Earnings from Continuing Operations | 19.27% | 26.62% | 32.77% | 48.31% | 58.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.27% | 26.62% | 32.77% | 48.31% | 58.07% |
| EBIT | 28.85% | 64.24% | 75.12% | 54.12% | 61.67% |
| EBITDA | 38.05% | 75.88% | 85.41% | 61.43% | 66.65% |
| EPS Basic | 29.41% | 39.66% | 51.08% | 62.74% | 67.70% |
| Normalized Basic EPS | 38.46% | 71.78% | 80.72% | 67.35% | 70.93% |
| EPS Diluted | 29.41% | 39.66% | 51.08% | 62.74% | 67.70% |
| Normalized Diluted EPS | 38.46% | 71.78% | 80.72% | 67.35% | 70.93% |
| Average Basic Shares Outstanding | 13.18% | 17.57% | 29.43% | 38.08% | 30.16% |
| Average Diluted Shares Outstanding | 13.18% | 17.57% | 29.43% | 38.08% | 30.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |